Former President and Chief Executive Officer · OnKure Therapeutics, Inc. (OKUR)

Gregory Flesher

A named executive officer of OnKure Therapeutics in every fiscal year CompBrief holds from FY2020 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$1,779,607

Salary $453,365Stock awards $0

FY2022: $1,193,452

4th of 4 named executive officers at OnKure Therapeutics by FY2024 total.

4 named officers on file for OnKure Therapeutics, FY2024

Gregory Flesher’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 4 equity grants, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how OnKure Therapeutics’s whole pay program stands against its peers

  • OnKure Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on OKUR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 16, 2025 (DEF 14A).

Free

Get Gregory Flesher’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Gregory Flesher compensation by year

OnKure Therapeutics Summary Compensation Table · all 4 fiscal years held
In US dollars, as OnKure Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021FY2022FY2024
Salary$79,167$475,000$545,000$453,365
Bonus$0$0$0$0
Stock awards$0$429,699$0$0
Option awards$0$4,196,725$393,000$0
Non-equity incentive$39,600$219,700$245,300$0
Pension and deferred compensation$0$0$0$0
All other$14,180$48,346$10,152$1,326,242
Total$132,947$5,369,470$1,193,452$1,779,607

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: OnKure Therapeutics, Inc. DEF 14A filed April 16, 2025, accession 0001140361-25-014183, and prior-year filings. Open the filing on EDGAR.

How this page was built: the OnKure Therapeutics, Inc. filed document, accession 0001140361-25-014183. Every figure is read from that document and cited to the page and table it appears in. Filed April 16, 2025.

$133K
$5.4M
$1.2M
$1.8M
FY20
FY21
FY22
FY24
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU10,000$86,000—

Per the Outstanding Equity Awards at Fiscal Year-End table in OnKure Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

OnKure Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Nicholas SaccomanoPresident and Chief Executive Officer$9,515,165
Samuel AgrestaChief Medical Officer$2,841,068
Jason LeveroneChief Financial Officer$2,678,570
Gregory Flesher · this pageFormer President and Chief Executive Officer$1,779,607

The full OnKure Therapeutics compensation record

free company brief

This page is one person within OnKure Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are OnKure Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Gregory Flesher's compensation dossier · One-time report. No refunds.